Want to see NRXP full AI Analyst Report?
NRXP Stock Chart & Stats
$2.55
-$0.69(-14.70%)
At close: 4:00 PM EST
$2.55
-$0.69(-14.70%)
Day’s Range― - ―
52-Week Range$1.62 - $5.06
Previous CloseN/A
Volume2.07M
Average Volume (3M)475.66K
Market Cap
$172.39M
Enterprise Value$63.02M
Total Cash (Recent Filing)$6.71M
Total Debt (Recent Filing)$934.00K
Price to Earnings (P/E)―
Beta0.84
Next Earnings
Aug 17, 2026EPS Estimate
-0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.28
Shares Outstanding41,943,280
10 Day Avg. Volume509,446
30 Day Avg. Volume475,656
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)-3.64
Price to Sales (P/S)47.35
P/FCF Ratio-4.11
Enterprise Value/Market Cap0.37
Enterprise Value/Revenue27.48
Enterprise Value/Gross Profit74.05
Enterprise Value/Ebitda-2.70
Forecast
1Y Price Target
$38.25Price Target Upside1400.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.37
Revenue Forecast (FY)$13.89M
Bulls Say, Bears Say
Bulls Say
Manufacturing Scale And Supply AdvantageNRx's blow-fill-seal manufacturing scale provides a durable supply-side advantage for KETAFREE: high throughput and the ability to hold meaningful launch inventory reduce reliance on constrained compounding supply, support consistent commercial supply, and raise barriers to quick competitive replication.
Regulatory And Clinical Progress Backed By Large RWEA NDA built on substantial clinical data plus >65,000-patient real-world evidence strengthens the regulatory case and potential label breadth. Fast Track engagement and FDA willingness to review RWE improve the probability and durability of approval and support broader commercial positioning if accepted.
Improved Liquidity And Reduced LeverageReduction to zero debt and a post-quarter capital raise materially improves near-term solvency and gives runway to execute regulatory and commercial milestones. Stronger liquidity reduces immediate bankruptcy/default risk and supports continued clinical programs and initial commercialization activities.
Bears Say
Persistent Heavy Cash BurnSustained negative operating and free cash flow means the business is not yet self-funding. Until revenue scales or structural cost reductions occur, the company will likely rely on external capital, creating dilution risk, constraining long-term investment choices, and making execution sensitive to capital markets.
Negative Shareholders' Equity And Small Asset BaseA sizable accumulated deficit and negative equity limit financial flexibility and borrowing capacity. With modest total assets, the balance sheet offers limited buffer against setbacks, complicates counterparty confidence for partnerships, and can increase the cost or reduce availability of non-dilutive financing.
Commercial And Execution Risks To Capture Clinic DemandCapturing clinic demand requires displacing compounding pharmacies and establishing payer/distributor relationships—a structural, multi-quarter effort. Even with approvals and supply, converting clinic prescribing and executing distribution represents sustained execution risk that affects durable revenue scaling.
NRX Pharmaceuticals News
NRXP FAQ
What was NRX Pharmaceuticals’s price range in the past 12 months?
NRX Pharmaceuticals lowest stock price was $1.62 and its highest was $5.05 in the past 12 months.
What is NRX Pharmaceuticals’s market cap?
NRX Pharmaceuticals’s market cap is $172.39M.
When is NRX Pharmaceuticals’s upcoming earnings report date?
NRX Pharmaceuticals’s upcoming earnings report date is Aug 17, 2026 which is in 37 days.
How were NRX Pharmaceuticals’s earnings last quarter?
NRX Pharmaceuticals released its earnings results on May 18, 2026. The company reported -$0.04 earnings per share for the quarter, missing the consensus estimate of $0.209 by -$0.249.
Is NRX Pharmaceuticals overvalued?
According to Wall Street analysts NRX Pharmaceuticals’s price is currently Undervalued.
Does NRX Pharmaceuticals pay dividends?
NRX Pharmaceuticals does not currently pay dividends.
What is NRX Pharmaceuticals’s EPS estimate?
NRX Pharmaceuticals’s EPS estimate is -0.11.
How many shares outstanding does NRX Pharmaceuticals have?
NRX Pharmaceuticals has 41,943,280 shares outstanding.
What happened to NRX Pharmaceuticals’s price movement after its last earnings report?
NRX Pharmaceuticals reported an EPS of -$0.04 in its last earnings report, missing expectations of $0.209. Following the earnings report the stock price went down -5.03%.
Which hedge fund is a major shareholder of NRX Pharmaceuticals?
Currently, no hedge funds are holding shares in NRXP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
NRX Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$38.25 (1400.00% Upside)
$38.25 (1400.00% Upside)
Hedge Fund Trend
Decreased
By 3.0M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 1.7%
Last 30 Days ▲ 3.5%
Last 30 Days ▲ 3.5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
164.80%
12-Months-Change
Fundamentals
Return on Equity
107.73%
Trailing 12-Months
Asset Growth
56.82%
Trailing 12-Months
Company Description
NRX Pharmaceuticals
NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm focused on developing innovative therapies for disorders of the central nervous system and critical lung diseases. Its product portfolio features ZYESAMI, an experimental medication that has successfully completed Phase IIb/III clinical trials for treating respiratory failure associated with COVID-19. Additionally, the company is advancing NRX-100 and NRX-101, a pair of oral therapeutics designed to address bipolar depression, specifically in patients exhibiting acute or sub-acute suicidal thoughts and behaviors. Established in 2015, NRx Pharmaceuticals is headquartered in Wilmington, Delaware.
NRXP Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized substantial forward progress across multiple fronts: near-term regulatory and manufacturing milestones for KETAFREE, an NRX-100 NDA supported by >65,000-patient RWE, FDA clearance to proceed with a sizable NRX-101 TMS augmentation trial (MIND1), expansion of HOPE clinics, and acquisition of Geneuro assets to broaden the pipeline. Financially, reported net loss improved materially (a 74% reduction year-over-year) and the company raised ~$7.0M post-quarter, while becoming debt-free. Counterbalancing these positives are near-term operational cash sensitivity, increased operating losses driven by higher R&D and G&A spend, ongoing regulatory timing risk, the need to build commercial channels (particularly to displace compounding pharmacy supply to clinics), and dependence on anticipated nondilutive funding for certain programs. Overall, the balance of concrete regulatory/operational advances and capital actions alongside manageable but material execution and timing risks supports a constructive outlook.View all NRXP earnings summariesNRXP Stock 12 Month Forecast
Average Price Target
$38.25
▲(1400.00% Upside)
Technical Analysis
CervoMed
―
―
Werewolf Therapeutics
―
OKYO Pharma Limited Sponsored ADR
―
CAMP4 Therapeutics Corporation
―
Ownership Overview
9.00%
Insiders
3.22% Mutual Funds
8.68% Other Institutional Investors
74.28% Public Companies and Individual Investors